CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 21 enrolled
Drug / intervention
Recombinant Human Growth Hormone +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00283595
NCT00283595Phase 2Completed
CompareCT.gov

Effect of Supraphysiological rhGH on Bone Metabolism in Patients With Anorexia Nervosa

Massachusetts General Hospital·interventional·Posted Jan 30, 2006·Updated Sep 2, 2020

In Brief

A Phase 2 clinical trial evaluating Recombinant Human Growth Hormone and Placebo for Recombinant Human Growth Hormone for Anorexia Nervosa and 3 related conditions. Completed, enrolled 21 participants across 1 site.

Detailed Summary

Decreased bone strength is a serious medical problem present in many women with Anorexia Nervosa, or disordered eating. Women with weaker bones are more likely to suffer broken bones than women with normal bone strength. We are investigating whether a hormone that is naturally produced by the human body, called growth hormone, can help strengthen the bones of women with this type of disordered eating.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAnorexia Nervosa, Osteopenia, Osteoporosis, Eating Disorders
CountriesUnited States
CollaboratorsGenentech, Inc.

Timeline

Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJan 30, 2006
Enrollment StartJan 1, 2006
Primary CompletionFeb 1, 2009
TodayJul 2, 2026
Enrollment to primary: 3.1 yearsPosted 20.4 years ago

Interventions

Recombinant Human Growth Hormonedrug

Dosage increased in steps for first four weeks. Self injection qd x 12 weeks

Placebo for Recombinant Human Growth Hormonedrug

Administered as Arm 1, rHGH active Injection qd x 12 weeks Dosage increase over four weeks